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WMD: Weighted mean differencesPropolis is a resin-like substance collected by honeybees from certain plants that have been shown to
positive effect on inflammatory factors. Therefore, the aim of this study was to systematically review
and meta-analyse the effects of Propolis supplementation on CRP, TNF-a, IL-1, and IL-6 in Randomized
Controlled Trials (RCTs). A comprehensive systematic search of articles was conducted in
PubMed/MEDLINE, Web of sciences, and Scopus to identify the potential titles up to August 2019.
PRISMA guidelines were performed for this study. Inclusion was 1-study design was parallel or cross over
randomized controlled trial (RCT), 2- consumption of Propolis as intervention, 3- reported sufficient
information about inflammatory factors, CRP, IL1, IL6, TNF-a. Six studies were identified by comprehen-
sive search. This meta-analysis study found a significant reduction in IL-6, CRP, and TNF-a following
Propolis consumption (Weighted mean differences (WMD): 17.96 pg/ml, 95% CI: 35.53, 0.38,
I2 = 98%), (WMD: 1.16 pg/ml, 95% CI: 2.28, 0.03, I2 = 97%), and (WMD: 34.08 pg/ml, 95% CI:
60.25, 7.91, I2 = 97%), respectively. Propolis did not showed any significant effect on IL-1 (WMD:
17.36 pg/ml, 95% CI: 37.60, 2.87, I2 = 97%). In conclusion, the results demonstrated that CRP, TNF-a
and IL-6 were significantly reduced following propolis supplementation.
 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access
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Propolis has been a part of human medicine for thousands of
years with the Egyptians, Greeks and Romans benefiting from its
property’s centuries ago. In the middle ages, the popularity of pro-
polis declined only to resurface in the early 1900 s thanks to
increasing research on its molecular properties (Kuropatnicki
et al., 2013). Propolis is a resin-like substance collected by honey-
bees from certain plants of which some of the commonest are
Eucalyptus citriodora, Baccharis dracunculifolia, and Araucaria
angustifolia (Szliszka et al., 2013). This substance is then used by
bees to glue together their hives as if it were a type of cement. Pro-
polis remains popular in over the counter medicine for its antiox-
idant and anti-inflammatory effects. Successful uses of propolis
include mouth wash, throat sprays, cough medicine, wound heal-
ing in diabetic foot ulcers and topical applications for acne vulgaris
(Ali et al., 2015; Henshaw et al., 2014; Khurshid et al., 2017). Cur-
rently, China is the world’s greatest producer and exporter with
strong research showing its anti-inflammatory effects in animal
models, however, studies demonstrating its mechanism at a
molecular level are still limited (Wang et al., 2013).
With the escalating concerns surrounding anti-microbial resis-
tance there has been a recent move towards reconsidering natural
substances and their anti-microbial and anti-inflammatory proper-
ties. For example, another substance related to bees, Manuka
Honey, is shown to contain high levels of methyl glyoxal (MGO),
leptosin and hydrogen peroxide. Manuka honey has been widely
tested and studies in vitro have confirmed that it is effective
against a range of different bacteria, especially those that often col-
onize skin wounds (Carter et al., 2016). Similarly, nanocrystalline
silver (nAg + ) has also been found to be effective in the treatment
of chronic wounds due to the electrostatic attraction between
nAg + and the negatively charged cell membranes of bacteria. Its
anti-inflammatory actions have been observed in vivo, but the
underlying molecular pathways are still unclear. Nevertheless,
in vitro research has shown it to suppress TNF-a, IL-8, IL-6 and
IL-12 (Nadworny et al., 2010; Tsang et al., 2015).
Since the early twentieth century research surrounding the
molecular mechanisms of propolis have increased correlated with
the advance of molecular chemistry. Today, propolis is known to be
high in flavonoid content, a substance originating from plants,
which has been found to inhibit the production of nitric oxide
(NO), IL-1 & IL-6 (Wang et al., 2013). In vitro studies have also
demonstrated the efficacy of flavonoids against over 25 strains of
bacteria and 20 strains of fungus that can cause disease in humans
(Tsang et al., 2015). Another immunomodulatory substance known
to be abundant in propolis is phenolic acids whose molecular activ-
ity diminish the quantity of NO, cytokines and neutrophils
(Szliszka et al., 2013).Undoubtedly, the number of studies evaluating the molecular
anti-inflammatory properties of propolis has been increasing.
However, to the best of our knowledge, no systematic review has
attempted to summarize this evidence. Our study will attempt to
summarize, critically evaluate and establish the dose response
relationship surrounding the effects of propolis on inflammatory
factors.
2. Methods
2.1. Literature search
For conducting this systematic review and meta-analysis
following Preferred Reporting Items of Systematic Reviews and
Meta-Analysis (PRISMA) statement guidelines was conducted
(Moher et al., 2011). Two study authors (G.K andG.R) independently
conducted a systematic search of the databases MEDLINE/PubMed,
Web of sciences, and Scopus (all years to August 5st 2019). MeSH
terms and title and/or abstract keywords used in the search strategy
(supplementary Table 1). Reference lists of included studies were
searched to avoid missing any relevant article. No language or date
restrictions was applied. Any disagreements between the authors
are resolved by senior author (QY).
2.2. Study selection
Screening of studies performed in title and/or abstract and full
text. The PICOS (patients: public population, intervention: propolis,
comparator: Placebo, outcome: CRP, TNF-a IL-1, and IL-6 study
design: RCTs) criteria was used to establish study Selection.
2.3. Eligibility criteria
We included studies that have a) the study design was parallel
or cross over randomized controlled trial (RCT), b) consumption of
Propolis c) reported sufficient information about inflammatory fac-
tors, CRP, TNF-a, IL1, and IL6. We excluded animal, in-vitro studies,
done on children, studies without placebo-control group or did not
report inflammatory factors, CRP, TNFa, IL1, and IL6 at baseline and
end of the intervention and non-original papers. Corresponding
authors were contacted for any additional details or missing data
of selected articles, when required.
2.4. Statistical analyses
Data was analyzed by STATA software version 12 (STATA Corp,
College119 station, Texas). Mean change and standard deviation
(SD) for CRP, TNFa, IL1, and IL6 were estimated using Weighted
mean difference (WMD) of the intervention. If the studies did not
1696 H. Shang et al. / Journal of King Saud University – Science 32 (2020) 1694–1701report SD change of the mean differences are calculated using
SD2 = [(SD baseline2 + SD final2) (2 r SD baseline SD final)]
formula (Higgins and Green, 2011). The heterogeneity among the
studies was assessment by the I-squared (I2) statistics and Q test.
Meta-regression based on duration of supplementation conducted
to find source of heterogeneity. Publication bias was assessed using
funnel plots and Egger’s and Begg’s tests of weighted regression
(Egger et al., 1997). The effect of each study on pooled results eval-
uated by sensitivity analysis. Quality assessment of randomized
control trials were assessed by the Cochrane collaboration’s tool
(Higgins et al., 2011).3. Results
In initial search from PubMed, Scopus, and web of sciences and
after removing duplicated studies, 814 articles were identified that
presented in Fig. 1. In first step, 791 paper removed based on title
and abstract screening and 23 articles were retrieved for more
evaluation. Finally, six article included in this meta-analysis and
17 article excluded because did not meet inclusion criteria
(Afsharpour et al., 2017; Fukuda et al., 2015; Khayyal et al.,
2003; Mujica et al., 2017; Zakerkish et al., 2019; Zhu et al., 2018).3.1. Mine characteristics of studies
Included studies Characteristics are presented in Table 1.
Included studies sample size was 63 ranged from 17 to 94, all stud-
ies conducted on both genders and mean age of participants was
57 years. Included studies were conducted Iran (Afsharpour et al.,
2017; Zakerkish et al., 2019), China (Zhu et al., 2018), Chile (Mujica
et al., 2017), Japan (Fukuda et al., 2015), and Egypt (Khayyal et al.,
2003). They were published between 2003 and 2019. Cochrane col-
laboration’s tool for quality assessment of randomized controlled
trials was used to assess the quality of included studies and most
of them had appropriate quality.Arcles included in qualitave synthesis
(n =6) 
Records idenfied thr
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Scopu
Web of sci
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en
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Total records 
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Fig. 1. Flow chart of included studi3.2. Meta-analysis results
Four studies with 279 participants reported IL-6 as an outcome
measure (Fukuda et al., 2015; Khayyal et al., 2003; M. Zakerkish
et al., 2019; Zhu et al., 2018) and pooled results showed a signifi-
cant reduction effect of Propolis on IL-6 (WMD: 17.96 pg/ml,
95% CI: 35.53, 0.38, I2 = %98) (Fig. 2). Meta-regression analysis
based on duration of intervention (Supplemental Fig. 1) show an
indirect relation between duration of intervention by Propolis
and levels of IL-6 (Coef = 0.1054) but this relation was not statis-
tically significant (p = 0.71). While, Propolis did not have any sig-
nificant reduction effect on IL-1 (WMD: 17.36 pg/ml, 95% CI:
37.60, 2.87, I2 = %97) and because low number of included stud-
ies in this outcome we could not run meta-regression analysis on
IL-1 (Zakerkish et al., 2019; Zhu et al., 2018).
Four studies with 301 participants (intervention = 156, con-
trol = 145) reported CRP as an outcome measure (Afsharpour
et al., 2017; Fukuda et al., 2015; Mujica et al., 2017; Zakerkish
et al., 2019) and combined results showed a significant reduction
on CRP by propolis consumption (WMD: 1.16 pg/ml, 95% CI:
2.28, 0.03, I2 = %97). Although Meta-regression analysis show
reverse relation between propolis supplementation and CRP levels
(Coef = -0.1350) but this coefficient was not significant (P = 0.70).
Propolis supplementation had significant reduction effect on TNF-a
levels (WMD: 34.08 pg/ml, 95% CI: 60.25, 7.91, I2 = %97)
(Afsharpour et al., 2017; Khayyal et al., 2003; Zakerkish et al.,
2019; Zhu et al., 2018). Meta-regression analysis show reverse
relation between propolis supplementation and TNF-a levels
(Coef = 0.4600) but was not significant (P = 0.21) (Fig. 3).3.3. Risk of bias and sensitivity analysis
There is not any asymmetry between included studies (Supple-
mental Fig. 3). No publication bias was identified in Egger’s and
begg’s tests for IL-6 (p = 0.23, p = 0.09), IL-1 (p=-, p = 0.31), CRP
(p = 0.40, p = 0.17), and TNF-a (p = 0.13, p = 0.49), respectively.Records excluded at tle and / or abstract 
(n=791)
Full-text arcles excluded (n=17):
Outcome data presented in an unsuitable format (n =5)
Studies without control groups (n=3)
Non-RCTs (n=9)
ough database searching
DLINE (n = 290)
s (n= 449) 
ences (n =611)
Records excluded because duplicated
(n=536)
es based on searched database.
Fig. 2. Cochrane risk of bias assessment of included studies.
Table 1
Characteristics of included studies.
Author Location year Participants
(n)
Gender Age
(year)
Dose (mg /
day)
Type of Propolis Duration
of study
(week)
Population study
Zakerkish Iran 2019 94 both 55.15 1000 Iranian propolis 12.85 T2DM adults duration < 10 years,
not using insulin, no severe renal or
hepatic dysfunction or serious
cardiovascular/hematological
disease, no allergies or pregnancy
Afsharpour Iran 2019 60 both 50.43 1500 Alamut propolis 8 T2DM, age 33–55,
duration < 10 years, not using
insulin, without serious disease
(e.g., CHD, kidney, hepatic failure,
cancer)
Zhu China 2018 60 both 72.8 66 mg
Artepillin C
Brazilian green propolis 104 Elderly people living at altitude
without dementia, mental illness, or
inflammatory conditions
Mujica Chile 2017 17 both 46.4 Unstated Beepolis (from Maule
region of Chile)
12.85 One of: altered FBS, altered lipids,
altered BP, or T2DM, or CVD, or
overweight. Exclusion: alcoholism,
serious pathologies.
Fukuda Japan 2015 80 both 63.31 226.8 Brazilian green propolis 8 T2DM, age 35–80, on non-insulin
treatment, without eGFR < 30
mL/min/1.73 m2 or hepatic
dysfunction
Khayyal Egypt 2003 67 both Unstated 2 mL of 13%
aqueous
extract of
propolis
solution
(=260 mg if
percentage
is w/v)
Aqueous decoction of
crude Danish, Chinese,
Uruguayan and Brazilian
propolis, standardized to
contain  0.05% aromatic
acids
8 Mild-to-moderate asthmatics of
duration 2–5 years, aged 19–52.
Excluded: adverse effects during
treatment, excessive rescue puffer
use, corticosteroids in last
2 months, allergy to drugs, acute
severe asthma in past 6 months,
other comorbidities like diabetes or
HTN requiring therapy
H. Shang et al. / Journal of King Saud University – Science 32 (2020) 1694–1701 1697Sensitivity analysis did not identified significant differences
beyond the limits of 95% CI between calculated SESs for metformin
intervention studies (Supplemental Fig. 3).4. Discussion
Propolis is known to possess a high flavonoid content and found
to inhibit the production of various inflammatory markers, includ-
ing Nitric Oxide, IL-1 & IL-6. Although the interest in the molecularanti-inflammatory properties of propolis has increased, with the
disease ameliorating and immunomodulatory effects being among
the most reported characteristics, to the best of our knowledge,
there has been no summative assessment of literature. Therefore,
we sought to investigate the effects of propolis supplement on
inflammatory factors. In accord with this aim, we found that IL-6,
CRP, and TNF-a were reduced following propolis supplementation,
whilst no significant effect was manifest in IL-1.
A higher pro-inflammatory cytokines such as TNF-a, IL1, and
IL6 and CRP are associated with oxidative stress and chronic
1698 H. Shang et al. / Journal of King Saud University – Science 32 (2020) 1694–1701inflammation in the pathogenesis of T2DM (Pradhan et al., 2001;
Zhao et al., 2016). Propolis possesses strong anti-inflammatory
function (Freires et al., 2016). It can directly influence a decrease
in pro-inflammatory cytokines (Al Ghamdi et al., 2015; Silva-
Carvalho et al., 2015). Whilst most studies are concordant that pro-
polis elicits a improvment impact on inflammation, and it can
decrease TNF levels, its effects on interleukins levels has beena) IL-6
NOTE: Weights are from random effects analysis
Overall  (I-squared = 98.7%, p = 0.000)
Khayyal (2003)
Fukuda (2015)
Zhu (2018)
Study
ID
Zakerkish (2019)
0-77.7
b) IL-1
NOTE: Weights are from random effects analysis
Overall  (I-squared = 97.0%, p = 0.000)
Study
ID
Zhu (2018)
Zakerkish (2019)
0-37.6
Fig. 3. Random effect model of meta-analysis of effect of propinconsistently reported (Orsatti et al., 2010; Silva-Carvalho et al.,
2015; Zakerkish et al., 2019). However, in this study, the first sum-
mative assessment in the literature, we highlight that IL-6 (WMD:
17.96 pg/ml, 95% CI: 35.53, 0.38, I2 = 98%), CRP (WMD:
1.16 pg/ml, 95% CI: 2.28, 0.03, I2 = 97%), and TNF-a levels
(WMD:34.08 pg/ml, 95% CI: 60.25,7.91, I2 = 97%) were all sig-
nificantly reduced following propolis supplementation, yet IL-1-17.96 (-35.53, -0.38)
-46.57 (-77.66, -15.48)
-0.60 (-0.80, -0.40)
-25.58 (-28.86, -22.30)
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100.00
15.17
28.88
28.59
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Weight
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-17.36 (-37.60, 2.87)
WMD (95% CI)
-27.74 (-33.09, -22.39)
-7.09 (-11.58, -2.60)
100.00
%
Weight
49.74
50.26
37.6
olis supplementation on: a) IL-6, b) IL-1, c) CRP, d) TNF-a.
c) CRP
NOTE: Weights are from random effects analysis
Overall  (I-squared = 97.2%, p = 0.000)
Zakerkish (2019)
ID
Fukuda (2015)
Afsharpour (2017)
Mujica (2017)
Study
-1.16 (-2.28, -0.03)
-2.67 (-3.12, -2.22)
WMD (95% CI)
-0.05 (-0.29, 0.19)
-1.83 (-3.31, -0.35)
-0.33 (-0.59, -0.07)
100.00
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Weight
27.38
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d) TNF-a
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Fig. 3 (continued)
H. Shang et al. / Journal of King Saud University – Science 32 (2020) 1694–1701 1699was not. In Zakerkish et al. study, by propolis supplementation in
T2DM patients, the level of CRP and TNF were decreased
(Zakerkish et al., 2019). However, no difference in serum IL-1 and
IL-6 levels were noticed. Intervention with Brazilian propolis
showed a reduction in serum TNF-a levels, however, IL-1 and IL-
6 serum levels were increased in Zhao et al. study. It is suggestedthat the IL-1 production pro-inflammatory effects may conceivably
have been be prevented by the anti-inflammatory effects of IL6.
Thus, propolis supplementation have positive effects on chronic
inflammation (Zhao et al., 2016).
Of interest, is the fact that, in the present meta-analysis, the
propolis administered to participants consisted of varying progeny.
1700 H. Shang et al. / Journal of King Saud University – Science 32 (2020) 1694–1701For instance, Brazilian, Iranian, Alamut and Chilean varieties were
identified. Propolis is largely comprised of phenols, terpenes, vita-
mins, amino acids, sugars, and elements (Bankova et al., 2014), and
is known to possess a complex chemical composition (Mercuri
et al., 2000; Silva-Carvalho et al., 2015). In the present study we
were unable to investigate the differing sources of propolis in
sub-group analyses, due to a lack of eligible studies. However,
we assert that varying species of propolis must be investigated
more acutely in future studies.
5. Putative mechanisms
Propolis contains propolins, steroids, phenols, aldehydes, terpe-
nes, phenolic acids, amino acids, flavonoids, and ketones (Trusheva
et al., 2010; Xuan et al., 2014). Moreover, the presence of caffeic
acid and chlorogenic acid in propolis helps to prevent LDL-C oxida-
tion (Bueno-Silva et al., 2015). DNA oxidative damage inhibit in
presence of chlorogenic acid by peroxynitrite scavenging and
reduces in the release of myeloperoxidase (Hu et al., 2005). Caf-
feoylquinic acid derivatives and artepillin C are considered for pro-
polis neuroprotective effects (Franchin et al., 2018), where propolis
inhibit of the activities of cyclooxygenases (COX-1 and COX-2),
impeding the gene expression of inducible nitric oxide synthase
(iNOS), and blocking TNF-a-mediated NF-қB activation (Banskota
et al., 2001; Woo et al., 2005). Caffeic acid phenethyl ester (CAPE)
inhibitor the NF-қB activation, which provide the molecular basis
for its anti-inflammatory activity (Tahira Farooqui and Farooqui,
2010).
The antioxidant activity of flavonoids, a constituent of propolis,
is attributed to their ability to reduce formation of free radical (Ahn
et al., 2009; Kumazawa et al., 2004). The propolis flavonoids in pos-
sess Fe2+ chelating can decrease peroxidation lipids (Van Acker
et al., 1996). Kumazawa et al (2007) showed that anti-oxidant
activity of flavonoid related to the geranyl or prenyl group position
in the flavonoid skeleton (Kumazawa et al., 2007). Furthermore,
propolis flavonoids exhibit antioxidant activity (Tahira Farooqui
and Farooqui, 2010). However, as asserted in Farooqui (Farooqui
and Farooqui, 2012), although propolis seems to elicit beneficial
effects on human health, the complex structure makes it difficult
to ascertain a true causal mechanism; in addition, Sforcin (2016).
suggested that the effects of propolis may be the result of several
components and not one specific compound.
6. Strengths and limitations
Main strength of this study was that this is the first meta-
analysis to assess the impact of propolis supplementation on
inflammatory markers. Through this investigation, we demon-
strated that there is sufficient evidence for propolis supplementa-
tion showed potential and positive effects on IL-6, CRP, and TNF-a.
The current study has some limitations to consider. The analy-
ses were not restricted to solitarily include patients of one type or
age; Furthermore, we could not find source of heterogeneity
between some results.
Furthermore, this is the first meta-analysis to assess the impact
of propolis supplementation on inflammatory markers, which per-
mits more nuanced guidance for further study.
7. Conclusion
Propolis has a several and useful chemical composition with
wide phytogeographic characteristics and is asserted to elicit
numerous positive biologic effects in humans. Prior to this work,
there was no summative assessment of the effect of propolis on
inflammatory markers; accordingly, we found that IL-6, CRP, andTNF-a were significantly reduced following propolis supplementa-
tion. Given that elevated inflammatory markers are associated
with a plethora of non-communicable diseases, propolis may rep-
resent a viable adjunct therapy.
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